D&O Insurance for Life Sciences, Stage by Stage

D&O is the one coverage line that every funding stage touches. The exposure profile shifts materially as the company moves from founder-led pre-seed through institutional Series A, growth-stage operations, and the pre-exit or pre-IPO conversation. The mistake most founders make is treating D&O as a one-time decision rather than a program that gets restructured at each stage.

Regulated-sector D&O is also structurally different from generic SaaS D&O. The interaction between FDA enforcement, HIPAA regulatory action, clinical trial disclosures, and securities risk produces a coverage need that generalist tech-startup placements do not anticipate. This walks through how D&O exposure looks at each stage, what the underwriting conversation tends to focus on, and how life sciences D&O differs from technology-segment D&O.

The Three-Side Structure

D&O is built in three sides. Side A indemnifies directors and officers personally when the company cannot or will not. Side B reimburses the company for indemnification it provides to its leadership. Side C covers the company directly for securities claims.

At pre-seed, the practical question is often whether D&O is in place at all. By Series A, the institutional director placed by the lead investor will require Side A separation as a condition of board service. At growth and pre-exit, all three sides matter and the structure of the tower (primary, excess layers, dedicated Side A) becomes the substantive conversation.

Pre-Seed and Founder Stage

Most pre-seed life sciences companies operate without D&O coverage. This is a defensible position when the company is founder-led, has not raised institutional capital, has no outside board members, and has not made forward-looking claims that could give rise to securities exposure. The exposure that does exist at this stage is primarily employment-related, founder dispute risk, and the early-stage regulatory engagement (FDA pre-submission meetings, initial CLIA application, early HIPAA exposure where applicable).

The decision point arrives when one of three things happens: the company raises a priced round, takes on an outside board member, or makes a public claim about product performance or regulatory progress. Any of those triggers the substantive D&O conversation.

For founders who anticipate raising within twelve months, putting a basic D&O policy in place ahead of the round is often easier than negotiating it under deadline pressure. The placement is small and the underwriting is light, but having a clean policy in force before diligence opens removes a checklist item. For the broader framing on what a first-time pre-seed or seed insurance buyer actually needs, including how D&O fits into the foundational placement, the companion piece walks through the early-stage program structure.

Seed Stage

Seed-stage D&O for a life sciences company looks similar to seed-stage D&O for any other technology company, with two differences. First, the regulatory engagement profile is more developed. Pre-IND meetings, FDA Q-Sub interactions, early CLIA conversations, and any clinical advisory relationships all sit inside the D&O exposure surface. Second, the founder background diligence runs heavier. Life sciences carriers typically ask about prior FDA or regulatory experience, prior company affiliations, and any history of regulatory action.

The practical placement at seed is often a basic management liability program (D&O packaged with EPLI and sometimes fiduciary liability) sized to the company’s actual employee count and risk profile. The Side A component is usually combined with Side B and C at this stage rather than separated.

The question at seed is not whether to buy D&O but whether the policy is structured to satisfy a lead investor at the next round. Founders who choose the cheapest available D&O product at seed often find themselves replacing the program entirely at Series A because the seed-stage placement does not anticipate institutional director requirements.

Series A

Series A is where D&O becomes a diligence item. The lead investor’s counsel will ask for in-force coverage summaries, sample certificates, and policy declarations. Three structural decisions get made.

First, Side A separation. The institutional director placed by the lead investor will typically require dedicated Side A capacity that responds when the company cannot indemnify. This is the structural protection that allows institutional directors to serve, and it is non-negotiable at most professional venture rounds.

Second, the entity and capacity structure of the program. Series A digital health, medical device, and clinical lab companies face different underwriting questions and different appetites. Companies with PHI exposure see harder cyber underwriting; companies with FDA-regulated products see harder products and regulatory questions; companies in mental health or substance use platforms see appetite restrictions. The structural choices that make sense at Series A are calibrated to segment.

Third, the timing of the placement relative to the close. A program placed 30 to 60 days before close allows underwriting to run on the merits. A program placed in the week of the close runs into rushed underwriting and narrower terms. For more on how Series A digital health diligence specifically treats insurance, see What insurance does a digital health startup need to raise a Series A?.

Series B

By Series B, several things have shifted. The company is larger, the board is more complex, the regulatory engagement is more developed, and the disclosure obligations to investors have multiplied. D&O at Series B typically restructures rather than incremental scales.

The tower grows. A single-layer primary placement that worked at Series A may need a structured tower with primary and excess layers at Series B. Side A separation is now standard. The Side B and C structure scales with the round size and the increasingly developed exposure to securities-style claims arising from clinical trial communications, business updates to investors, and product performance representations.

Management liability often separates into discrete policies. EPLI may carry its own primary placement rather than packaging with D&O. Fiduciary liability may become its own line. The integrated management liability product that was efficient at seed and adequate at Series A frequently becomes the wrong structure at Series B.

Growth Stage

Growth-stage life sciences D&O addresses three exposures that were less material earlier. First, FDA regulatory exposure has expanded. A Class II medical device manufacturer at commercialization faces products and regulatory defense issues that interact with D&O for any board-level decisions about quality, recall posture, or post-market surveillance. For the broader Class II program context, see What insurance does a Class II medical device manufacturer need before commercialization?.

Second, securities risk has matured. Forward-looking statements about clinical trial readouts, regulatory clearance timelines, or commercial performance can give rise to securities claims if the actual outcome materially differs. Growth-stage D&O underwriting focuses heavily on disclosure practices, internal review of forward-looking communications, and the company’s track record of meeting public commitments.

Third, executive transitions become more frequent. Growth-stage companies typically bring in operating executives, replace some founders in key roles, and add independent directors. D&O coverage for departed executives (run-off considerations) becomes a real question.

Pre-Exit and Pre-IPO

The D&O conversation in the twelve to twenty-four months before an exit or public offering is its own discipline. The exposure profile changes materially.

Pre-IPO, the company is subject to heightened SEC scrutiny, an S-1 disclosure regime, road-show communications obligations, and IPO allocation litigation risk. D&O at this stage typically restructures into a dedicated pre-IPO tower with primary, excess, and side-A capacity sized to the IPO transaction and the projected market cap. Public-company D&O follows.

Pre-acquisition, the structural questions are different. Run-off coverage (tail coverage) for the selling company’s directors and officers becomes the central question. A six-year tail is standard; the specific terms, exclusions, and acceptable carrier choices are negotiated as part of the transaction. The acquirer’s program needs to address acquired-entity risk under its own D&O.

The Growth-Stage Underwriting Pattern

Growth-stage D&O placements share a recognizable underwriting pattern that affects how the program is built.

FDA correspondence review. Carriers writing growth-stage D&O typically ask for a full inventory of FDA correspondence: pre-submission meetings, IND or IDE history, clearance pathway, 483 history, Warning Letter history, and any consent decree status. The depth of this review is materially greater than at Series A.

Forward-looking disclosure review. Public statements, investor communications, earnings-style updates to existing investors, and any pre-public-offering disclosure activity. Carriers want to see internal review of these communications and a track record of meeting publicly stated commitments.

Board-level decision documentation. Minutes of board meetings, committee structure, independent director arrangements, and the documentation of significant board-level decisions. The substance of board governance affects underwriting.

Claims and incident history. Prior D&O claims, securities-related demand letters, regulatory actions affecting individual officers, and any pending matters. Loss runs are read in detail.

Capital structure and disclosure trajectory. The company’s capital structure (institutional ownership, secondary market activity, employee equity), the disclosure obligations that have evolved, and the trajectory toward exit or public offering all factor into structure decisions.

The placement timeline at growth stage runs longer than at Series A or Series B. A clean growth-stage D&O placement that addresses the full structural conversation typically requires 60 to 90 days, not the 30 to 45 days that may have been sufficient earlier.

How Life Sciences D&O Differs From SaaS D&O

The four structural differences between life sciences D&O and generic SaaS D&O.

FDA and regulatory enforcement exposure. Warning Letters, 483s, consent decrees, and adverse inspection findings create regulatory defense exposure that interacts with D&O. SaaS D&O does not anticipate this dimension.

HIPAA and OCR exposure. Where the company touches PHI, OCR enforcement (now extended through the Risk Analysis Initiative) creates regulatory defense and entity coverage triggers that generic D&O does not address.

Clinical disclosure risk. Forward-looking statements about trial readouts, clearance timelines, or commercial milestones produce securities risk profiles that look different from SaaS revenue or growth claims.

Carrier appetite concentration. The specialty markets writing life sciences D&O are a narrower group than those writing technology D&O. Appetite is more selective, underwriting questions are more substantive, and program structure choices have less room for error.

Underwriting Factors at Every Stage

Six dimensions show up across all stages.

FDA correspondence and regulatory history. Pre-submission meetings, IND or IDE history, clearance pathway, 483 history, Warning Letter history.

Founder and executive background. Prior company affiliations, prior regulatory experience, and any history of executive-level regulatory or securities action.

PHI and HIPAA exposure. Whether the company touches PHI, the BAA structure, and the cyber control posture.

Board composition. Independent directors, institutional directors, board observer arrangements, and board committee structure.

Disclosure practices. Internal review of investor communications, public statements, and forward-looking claims.

Insurance history. Prior D&O programs, claims history, and prior carrier relationships.

Common Mistakes Across Stages

Buying seed-stage D&O without anticipating Series A diligence. The product that is cheapest at seed may not satisfy the lead investor’s counsel at Series A.

Underestimating Side A requirements. Institutional directors require Side A separation. A program that lacks it will be replaced.

Failing to restructure at Series B. The Series A program rarely scales to Series B without structural changes. Treating renewal as a price negotiation rather than a program redesign leaves gaps.

Missing run-off considerations at exit. Tail coverage decisions made under transaction deadline pressure produce worse terms than decisions made deliberately.

Treating D&O as a tech-startup product. Life sciences D&O is its own market. Generic startup D&O programs do not address regulatory enforcement, HIPAA exposure, or clinical disclosure risk.

A Note on Placement

MedTech Coverage works with life sciences companies on D&O programs structured around stage, segment, board composition, and the company’s specific regulatory and disclosure profile. Coverage is placed through Tower Street Insurance’s appointments with the specialty markets that write D&O across the life sciences segment at every funding stage.

If a D&O program is being placed for the first time, restructured at Series A or Series B, or evaluated against a pending exit or public offering, a structured coverage review produces a working document calibrated to the company’s actual stage and exposure profile.